➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Boehringer Ingelheim
Medtronic
AstraZeneca
Johnson and Johnson

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DAPAGLIFLOZIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Dapagliflozin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00162305 ↗ A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects Completed Bristol-Myers Squibb Phase 2 2005-04-01 The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
NCT00162305 ↗ A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects Completed AstraZeneca Phase 2 2005-04-01 The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
NCT00263276 ↗ A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus Completed Bristol-Myers Squibb Phase 2 2005-12-01 The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied
NCT00263276 ↗ A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus Completed AstraZeneca Phase 2 2005-12-01 The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied
NCT00357370 ↗ A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes Completed AstraZeneca Phase 2/Phase 3 2006-10-01 The purpose of this clinical research study is to learn if BMS-512148, added to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can help reduce the blood sugar levels compared to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone) alone, in subjects with type 2 diabetes. The safety of this treatment will also be studied.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dapagliflozin

Condition Name

Condition Name for Dapagliflozin
Intervention Trials
Type 2 Diabetes Mellitus 49
Diabetes Mellitus, Type 2 45
Type 2 Diabetes 42
Heart Failure 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dapagliflozin
Intervention Trials
Diabetes Mellitus 166
Diabetes Mellitus, Type 2 156
Heart Failure 31
Diabetes Mellitus, Type 1 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dapagliflozin

Trials by Country

Trials by Country for Dapagliflozin
Location Trials
United States 839
Canada 170
Mexico 97
India 52
China 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dapagliflozin
Location Trials
Texas 58
California 46
Florida 43
New York 34
Missouri 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dapagliflozin

Clinical Trial Phase

Clinical Trial Phase for Dapagliflozin
Clinical Trial Phase Trials
Phase 4 109
Phase 3 76
Phase 2/Phase 3 8
[disabled in preview] 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dapagliflozin
Clinical Trial Phase Trials
Not yet recruiting 114
Recruiting 89
Completed 76
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dapagliflozin

Sponsor Name

Sponsor Name for Dapagliflozin
Sponsor Trials
AstraZeneca 147
Bristol-Myers Squibb 44
The University of Texas Health Science Center at San Antonio 11
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dapagliflozin
Sponsor Trials
Other 264
Industry 234
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
AstraZeneca
Colorcon
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.